image
Qualigen Therapeutics, Inc. QLGN
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 3.16
-3.19 %
$ 2.33 M
Market Cap
-0.18
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one QLGN stock under the worst case scenario is HIDDEN Compared to the current market price of 3.16 USD, Qualigen Therapeutics, Inc. is HIDDEN

QLGN Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one QLGN stock under the base case scenario is HIDDEN Compared to the current market price of 3.16 USD, Qualigen Therapeutics, Inc. is HIDDEN

QLGN Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one QLGN stock under the best case scenario is HIDDEN Compared to the current market price of 3.16 USD, Qualigen Therapeutics, Inc. is HIDDEN

QLGN Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart QLGN

image
1M -19%
6M -33%
1Y -343%
3Y -7947%
5Y -64932.0%
All
$4.4$4.4$4.2$4.2$4.0$4.0$3.8$3.8$3.6$3.6$3.4$3.4$3.2$3.2$3.0$3.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
5.2 M REVENUE
4.44%
Growth Rates
1Year 4.44%
3Years 6.52%
5Years -2.15%
7Years 0.00%
10Years 0.00%
-11.3 M OPERATING INCOME
36.99%
Growth Rates
1Year 36.99%
3Years -0.00%
5Years -60.69%
7Years 15.46%
10Years -18.27%
-12.5 M NET INCOME
40.69%
Growth Rates
1Year 40.69%
3Years 15.15%
5Years 5.86%
7Years 5.39%
10Years -19.53%
-10.3 M OPERATING CASH FLOW
22.22%
Growth Rates
1Year 22.22%
3Years -1.84%
5Years 5.02%
7Years 5.41%
10Years -18.07%
4.22 M INVESTING CASH FLOW
2394.23%
Growth Rates
1Year 2394.23%
3Years 204.59%
5Years 21.10%
7Years 144.67%
10Years 85.68%
-550 K FINANCING CASH FLOW
-18.90%
Growth Rates
1Year -18.90%
3Years -0.54%
5Years -1.93%
7Years -1.18%
10Years -6.37%
0 REVENUE
0.00%
Growth Rates
1Year 4.44%
3Years 6.52%
5Years -2.15%
7Years 0.00%
10Years 0.00%
-1.27 M OPERATING INCOME
27.13%
Growth Rates
1Year 36.99%
3Years -0.00%
5Years -60.69%
7Years 15.46%
10Years -18.27%
-1.79 M NET INCOME
-21.50%
Growth Rates
1Year 40.69%
3Years 15.15%
5Years 5.86%
7Years 5.39%
10Years -19.53%
-1.8 M OPERATING CASH FLOW
-22.06%
Growth Rates
1Year 22.22%
3Years -1.84%
5Years 5.02%
7Years 5.41%
10Years -18.07%
-1.25 M INVESTING CASH FLOW
-357.14%
Growth Rates
1Year 2394.23%
3Years 204.59%
5Years 21.10%
7Years 144.67%
10Years 85.68%
3.32 M FINANCING CASH FLOW
188.64%
Growth Rates
1Year -18.90%
3Years -0.54%
5Years -1.93%
7Years -1.18%
10Years -6.37%
Balance Sheet Qualigen Therapeutics, Inc.
image
Current Assets 1.17 M
Cash & Short-Term Investments 402 K
Receivables 0
Other Current Assets 765 K
Non-Current Assets 866 K
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 866 K
19.76 %37.62 %42.62 %Total Assets$2.0m
Current Liabilities 4.14 M
Accounts Payable 2.22 M
Short-Term Debt 1.3 M
Other Current Liabilities 615 K
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
53.74 %31.41 %14.86 %Total Liabilities$4.1m
EFFICIENCY
Earnings Waterfall Qualigen Therapeutics, Inc.
image
Revenue 5.2 M
Cost Of Revenue 5.21 M
Gross Profit -4.5 K
Operating Expenses 6.1 M
Operating Income -11.3 M
Other Expenses 1.17 M
Net Income -12.5 M
6m6m4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)5m(5m)(4k)(6m)(11m)(1m)(12m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-0.09% GROSS MARGIN
-0.09%
Averages
1Year -0.09%
3Years 12.31%
5Years -0.30%
7Years 3.45%
10Years 2.42%
-217.20% OPERATING MARGIN
-217.20%
Averages
1Year -217.20%
3Years -326.03%
5Years -253.52%
7Years -206.42%
10Years -144.49%
-257.79% NET MARGIN
-257.79%
Averages
1Year -257.79%
3Years -332.14%
5Years -300.55%
7Years -229.13%
10Years -160.39%
637.83% ROE
637.83%
Averages
1Year 637.83%
3Years 79.69%
5Years 44.04%
7Years 24.05%
10Years -48.70%
-659.89% ROA
-659.89%
Averages
1Year -659.89%
3Years -282.83%
5Years -193.33%
7Years -144.13%
10Years -140.37%
1404.94% ROIC
1404.94%
Averages
1Year 1404.94%
3Years 373.36%
5Years 109.67%
7Years 66.26%
10Years -68.17%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Qualigen Therapeutics, Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)20152015201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -12.5 M
Depreciation & Amortization 4.5 K
Capital Expenditures 0
Stock-Based Compensation 1.1 M
Change in Working Capital 1.11 M
Others -536 K
Free Cash Flow -10.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Qualigen Therapeutics, Inc.
image
QLGN has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Qualigen Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on May 19, 2025 (the "Notice"). The Notice indicated that the Nasdaq Hearings Panel (the “Panel”) will consider the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 as an additional basis for delisting the Company's securities from The Nasdaq Stock Market. globenewswire.com - 1 month ago
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on April 24, 2025 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c) (the “Listing Rule”) as a result of its failure to timely file its Annual Report on Form 10-K for the annual period ended December 31, 2024 (the “2024 Form 10-K”), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the “Form 12b-25”) filed with the Securities and Exchange Commission (the "SEC") on April 1, 2025. The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC. globenewswire.com - 2 months ago
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of private placement of 5,100 Series A-2 Preferred Shares, with a stated value of US$1,000 per share, for its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (“Qualigen” or the “Company”), a life science company focused on developing platform treatments for adult and pediatric cancers, with the potential for orphan drug designations. globenewswire.com - 7 months ago
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on November 5, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, November 5, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol "QLGN." The new CUSIP number for the common stock will be 74754R 301. globenewswire.com - 8 months ago
Qualigen Therapeutics, Inc. Announces management changes. CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives. globenewswire.com - 9 months ago
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasdaq indicating that the Nasdaq Hearings Panel (“Panel”) has granted an extension for the continued listing of the Company, subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 19, 2024. The Company is diligently working to fulfill the requirements set forth by the Panel to ensure the Company's continued listing on Nasdaq. globenewswire.com - 9 months ago
Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) New York, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the “Offering”) of (i) 14,724,058 shares of common stock priced at $0.130 per share, with pre-funded warrants exercisable for 11,972,754 shares with respect to the registered direct offering for its client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. globenewswire.com - 9 months ago
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the closing of its previously announced public offering of 14,724,058 shares of common stock, par value $0.001 per share (each a “Share,” and collectively, the “Shares”) at public offering price of $0.13 per Share and pre-funded warrants to purchase up to 11,972,754 Shares at a price of $0.129 per share with an exercise price of $0.001 per share (the “Pre-Funded Warrants”). The Pre-Funded Warrants are exercisable upon issuance and will remain exercisable until all the Pre-Funded Warrants are exercised in full. globenewswire.com - 10 months ago
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stock, par value $0.001 per share (each a “Share,” and collectively, the “Shares”) at a public offering price of $0.13 per Share and pre-funded warrants to purchase up to 11,972,754 Shares at a price of $0.129 per pre-funded warrant with an exercise price of $0.001 per share (the “Pre-Funded Warrants”). The Pre-Funded Warrants are exercisable upon issuance and will remain exercisable until exercised in full. The closing of the offering is expected to occur on or about September 6, 2024, subject to the satisfaction of customary closing conditions. globenewswire.com - 10 months ago
Why Is Qualigen Therapeutics (QLGN) Stock Down 22% Today? Qualigen Therapeutics (NASDAQ: QLGN ) stock is falling on Monday as the clinical-stage therapeutics company's shares come off of a massive rally on Friday. That Friday rally resulted in shares of QLGN stock closing out normal trading hours up 109.2%. investorplace.com - 11 months ago
Why Is Qualigen (QLGN) Stock Up 141% Today? Qualigen (NASDAQ: QLGN ) stock is rocketing higher on Friday after the clinical-stage therapeutics company secured a new loan. Qualigen reached an agreement with an investor for a $2 million Senior Note due July 8, 2025 with an 18% annual interest rate. investorplace.com - 11 months ago
Why Is Qualigen Therapeutics (QLGN) Stock Down 12% Today? Qualigen Therapeutics (NASDAQ: QLGN ) stock is sliding lower on Monday as the clinical-stage therapeutics company's shares come off of a rally on Friday. That rally saw shares of QLGN stock soar more than 59% higher during normal trading hours. investorplace.com - 11 months ago
8. Profile Summary

Qualigen Therapeutics, Inc. QLGN

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 2.33 M
Dividend Yield 0.00%
Description Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Contact 2042 Corte Del Nogal, Carlsbad, CA, 92011 https://qlgntx.com
IPO Date June 23, 2015
Employees 4
Officers Mr. Michael S. Poirier Chief Operating Officer Mr. Kevin A. Richardson II Interim Chief Executive Officer, Interim Chief Financial Officer & Chairman of the Board Mr. Robert W. Campbell Becher President & Director Mr. Christopher L. Lotz Vice President of Finance & Corporate Secretary